Relook at lipoprotein (A): Independent risk factor of coronary artery disease in North Indian population

Indian Heart Journal

Volumn 66, Issue 3, 2014, Pages 272-279

  Yusuf, Jamal ^a   Yadav, Neeraj ^b   Mukhopadhyay, Saibal ^a   Goyal, Abhishek ^c   Mehta, Vimal ^a   Trehan, Vijay ^a   Tyagi, Sanjay ^a  

^a G B PANT HOSPITAL   (India)

^b Sterling Hospital   (India)

^c DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Coronary artery disease; Lp(a) Lipoprotein(a); North Indian population; Risk factors

Indexed keywords

EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; FEMALE; HIGH RISK PATIENT; HUMAN; INDIAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; RISK ASSESSMENT; SMOKING; STABLE ANGINA PECTORIS; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY; VASCULAR DISEASE; BLOOD; INDIA; PROCEDURES; RISK FACTOR;

BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; HUMANS; INDIA; LIPOPROTEIN(A); RISK ASSESSMENT; RISK FACTORS;

EID: 84903395477     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ihj.2014.03.002     Document Type: Article

References (46)

1. R. Gupta, S. Kastia, and S. Rastogi et al. Lipoprotein (a) in Coronary heart disease: a case-control study Ind Heart J 52 2000 407 410
2. J.K. Gambhir, H. Kaur, and D.S. Gambhir et al. Lipoprotein (a) as an independent risk factor for Coronary artery disease in patients below 40 years of age Ind Heart J 52 2000 411 415
3. D. Rajasekhar, K.S.S. Saibaba, and P.V.L.N.S. Rao et al. Lipoprotein (a): better assessor of coronary heart disease risk in South Indian population Ind J Clin Biochem 19 2004 53 59
4. E.A. Enas, V. Chako, and A. Senthilkumar et al. Elevated lipoprotein (a)-A genetic risk factor for premature vascular disease in people with or without standard risk factors: a review Dis Mon 52 2006 5 50
5. H.H. Hobbs, and A.L. White Lipoprotein(a): intrigues and insights Curr Opin Lipidol 10 1999 225 236
6. M. Jauhiainen, P. Koskinen, and C. Ehnholm et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants Atherosclerosis 89 1991 59 67
7. P.M. Ridker, C.H. Hennekens, and M.J. Stampfer A prospective study of lipoprotein(a) and the risk of myocardial infarction JAMA 270 1993 2195 2199
8. P.R. Kamstrup, A. Tybjaerg-Hansen, and R. Steffensen et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction JAMA 301 2009 2331 2339
9. The Emerging Risk Factors Collaboration S. Erqou, S. Kaptoge, and P.L. Perry et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 2009 412 423
10. F.S. Geethanjali, K. Luthra, and A. Lingenhel et al. Analysis pf the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease Atheroscelerosis 169 2003 121 130
11. R. Gupta, S. Vashisht, and V.K. Bahl et al. Correlation of lipoprotein (a) to angiographically defined coronary artery disease in Indians Intern J Cardiol 57 1996 265 270
12. S. Vashisht, R. Gulati, and L.M. Srivastava et al. Apolipoprotein (a) polymorphism and its association with plasma lipoprotein (a): a North Indian study Ind Heart J 52 2000 165 170
13. F. Ashfaq, P.K. Goel, and R. Sethi et al. Lipoprotein (a) levels in relation to severity of coronary artery disease in North Indian patients Heart Views 14 2013 12 16
14. E.M. Antman, M. Cohen, and P.J. Bernink et al. The TIMI risk score for unstable angina/non-ST elevation Mi: a method for prognostication and therapeutic decision making JAMA 284 2000 835 842
15. W.T. Friedwald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
16. K. Berg A new serum type system in man - the Lp system Acta Pathol Microbiol Scand 59 1963 369 382
17. Y. Li, M.M. Luke, and D. Shiftman et al. Genetic variants in the apolipoprotein (a) gene and coronary heart disease Circ Cardiovasc Genet 4 2011 565 573
18. F. Kronenberg, and G. Utermann Lipoprotein (a): resurrected by genetics J Intern Med 273 2013 6 30
19. A. Helgadottir, S. Gretarsdottir, and G. Thorleifsson et al. Apolipoprotein (a) genetic sequence variants associated with systemic atherosclerosis and coronary atheroscelerotic burden but not with venous thromboembolism J Am Coll Cardiol 60 2012 722 729
20. S. Erqou, A. Thompson, and E. Di Angelantonio et al. Apolipoprotein (a) isoforms and the risk of vascular disease: systemic review of 40 studies involving 58,000 participants J Am Coll Cardiol 55 2010 2160 2167
21. J.W. Mclean, J.E. Tomlinson, and W.J. Kuang et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen Nature 330 1987 132 137
22. S.M. Marcovina, J.J. Albers, and B. Gabel et al. Effect of the number of apolipoprotein (a) kringle 4 domains on immunochemical measurements of lipoprotein (a) Clin Chem 41 1995 246 255
23. S.M. Marcovina, M.L. Koschinsky, and J.J. Albers et al. Report of the National Heart, Lung and Blood Institute Workshop on Lipoprotein(a) and cardiovascular disease: recent advances and future directions Clin Chem 49 2003 1785 1796
24. F. Dati, J.R. Tate, S.M. Marcovina International Federation of Clinical Chemistry and Laboratory Medicine; IFCC Working Group for Lipoprotein(a) Assay Standardization First WHO/IFCC International reference reagent for lipoprotein (a) for immunoassay - Lp(a) SRM 2B Clin Chem Lab Med 42 2004 670 676
25. J.D. Morrisett The role of lipoprotein(a) in atherosclerosis Curr Atheroscler Rep 2 2000 243 250
26. S. Vashisht, H.S. Wasir, and L.M. Srivastava Association between incidence of lipoprotein positivity and coronary heart disease Ind Heart J 44 1992 223 226
27. R.C. Hoogeveen, J.K. Ghambir, and D. Gambhir et al. Evaluation of Lp(a) and other independent risk factors for CHD in Asian Indians and their USA counterparts J Lipid Res 42 2001 631 638
28. G. Luc, J.M. Bard, and D. Arveiler et al. Lipoprotein(a) as predictor of coronary heart disease: the PRIME Study Atherosclerosis 163 2002 377 384
29. P.M. Sweetnam, C.H. Bolton, and L.G. Downs et al. Apolipoproteins A-I, A-II and B, Lp(a) and the risk of ischaemic heart disease: the Caerphilly study Eur J Clin Invest 30 2000 947 956
30. N. Rifal, and J. Ma Apolipoprotein(a) concentration and further risk of angina pretoris with evidence of severe coronary atherosclerosis in men: the Physicians Health Study Clin Chem 50 2004 1364 1371
31. B.G. Nordestgaard, M.J. Chapman, and K. Ray et al. Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 31 2010 2844 2853
32. W. Wang, D. Hu, and E.T. Lee et al. Lipoprotein (a) in American Indians is low and not independently associated with cardiovascular disease. The Strong Heart Study Ann Epidemiol 12 2002 107 114
33. S.S. Anand, E.A. Enas, and J. Pogue et al. Elevated lipoprotein(a) levels in South Asians in North America Metabolism 47 1998 182 184
34. G. Dangas, R. Mehran, and P.C. Harpel et al. Lipoprotein(a) and inflammation in human coronary atheroma association with severity of clinical presentation J Am Coll Cardiol 32 1998 2035 2042
35. P. Stubbs, M. Seed, and D. Moseley et al. A prospective study of the role of lipoprotein(a) on the pathogenesis of unstable angina Eur Heart J 18 1997 603 607
36. J.D. Zampoulkis, A.A. Kyriakousi, and K.A. Poralis et al. Lipoprotein(a) is related to the extent of lesions in the coronary vasculature and to unstable coronary syndromes Clin Cardiol 23 2000 895 900
37. T. Budde, C. Fechtrup, and E. Bosenberg et al. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis Arterioscler Thromb 14 1994 1730 1736
38. R.B. Panwar, R. Gupta, and B.K. Gupta et al. Atherothrombotic risk factors & premature coronary heart disease in India: a case - control study Indian J Med Res 134 2011 J 26 32
39. G.M. Kostner, D. Gavish, and B. Leopold et al. HMG Co A reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels Circulation 80 1989 1313 1319
40. H.K. Berthold, and I.G. Berthold Hyperlipoproteinemia(a): clinical significance and treatment options Atheroscler Suppl 14 2013 1 5
41. W.E. Boden, J.L. Probstfield, and T. Anderson et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
42. J.J. Albers, A. Slee, and K.D. O'Brien et al. Relationship of apolipoprotein A-1 and B and lipoprotein(a) to cardiovascular outcomes in the AIM-High trial J Am Coll Cardiol 62 2013 1575 1579
43. R. Haynes, L. Jiang, and J.C. Hopewell et al. HPS2-THRIVE randomised placebo controlled trial in 25673 high risk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
44. B.R. Jaeger, Y. Richter, and D. Nagel et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events Nat Clin Pract Cardiovasc Med 6 2009 229 239
45. I. Chennamsetty, T. Claude, and K.M. Kostner et al. Farnesoid X receptor hepatic human APO A gene expression J Clin Invest 121 2011 3724 3734
46. M.H. Davidson, C.M. Ballantyne, and T.A. Jacobson et al. Clinical utility of inflammatory markers and advance lipoprotein testing: advice from an expert panel of lipid specialists J Clinl Lipidol 5 2011 338 367